The first pick would be in the pharma space, we are seeing quite good momentum here today, so pharma you can see Syngene which is giving you a good fresh breakout above 700 level so I think it is looking quite positive from current levels to test higher targets of 720, 725.
IndusInd’s back in black for Q4 with Rs 594 cr profit; provisions, slippages fall
In a remarkable financial turnaround, IndusInd Bank reported a net profit of ₹594 crore for the quarter ending March 2026. This surge was largely due
April 25, 2026